Ai Feedback
Exact(25)
However, the major bleeding rates in the RECORD studies without excluding major wound bleedings were reported in an FDA review, 38 and were similar to the major bleeding rates of the remaining studies.
Major bleeding rates were available in all studies (n=32 287).
Major bleeding rates were decreased with high- and low-dose edoxaban compared with warfarin [ 25].
There was no difference in major bleeding rates between the groups.
Major bleeding rates were 6.9%, 7.1%, and 5.1%, respectively (P = 0.91 and P = 0.35, respectively, vs clopidogrel).
Major bleeding rates for dabigatran 110 and 150 mg were similar to warfarin in this patient group [ 93].
Similar(35)
The largest observed major bleeding rate in observational studies occurred in the largest study.
This finding is consistent with the median major bleeding rate observed across our included studies (2.0 per 100 patient-years).
The major bleeding rate and total bleeding rate were significantly higher in the GP IIb/IIIa group, though the minor bleeding rate was not significantly different.
34 In Matisse trials, at therapeutic dose of 7.5 mg/day, bleeding risk of fondaparinux was comparable with therapeutic doses of UFH or LMWH (major bleeding rate of 1.1%1.3%% for all three substances).
Two early review articles summarized that warfarin therapy resulted in major bleeding rate in an average of 1.7%to3%3% of patients per year, and fatal bleeding in 0.6% to 0.8% of patients per year [ 50, 51].
Related(20)
severe bleeding rates
major hemorrhage rates
serious bleeding rates
important bleeding rates
major bleeding averages
major graduation rates
major benchmark rates
major mishap rates
major morbidity rates
major malformation rates
major complication rates
major resection rates
major discrepancy rates
major revision rates
major injury rates
major exchange rates
major disability rates
major crime rates
major amputation rates
major bleeding complications
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com